1 |
Ginsberg RJ, Vokes EE, Raben A. Cancer of the lung. Nonsmall cell lung cancer. In: de Vita, Ur, VT, Hellman S, Rosenber SA, edtiors. Cancer. Principles and practices of oncology. 5th ed. Philadelphia, Lippincott-Raven, 1997;858-911
|
2 |
Jackson DG, Schenker T, Waibel R, Bell JI, Stahel RA. Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer Suppl 1994;8110-5
|
3 |
Griffioen AW, Coenen MJ, Damen CA, et al. CD44 is involved in tumor angioenesis; an activation antigen on human endothelial cells. Blood 1997;90:1150-9
|
4 |
Mayer B, Jauch KW, Gunthert U, et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993;342: 1019-22
DOI
ScienceOn
|
5 |
Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S, Jagidar J. CD44 and its v6 spliced variant in lung tumors. A role in histogenesis? Cancer 1997;80:34-41
DOI
ScienceOn
|
6 |
Tran TA, Kallakury BVS, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997;28:809-14
DOI
ScienceOn
|
7 |
Fontanini G, Bigini D, Vignata S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177:57-63
DOI
ScienceOn
|
8 |
Rosvold E. Prognostic factors for patients with non-small cell cancer. In: Williams SD, Goulet R, Thomas G, editors. Current problems in cancer. Newer aspects in the diagnosis, treatment, and prevention of non-small cell lung cancer. Part II. Curr Probl Cancer 1996;20:272-8
DOI
ScienceOn
|
9 |
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. 1992; Proc Natl Acad Sci USA 89:12160-4
|
10 |
Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumours. Cancer Res 1994;54:1381- 87
|
11 |
Auerbach P. Natural history of carcinoma of the lung, In: Fisherman AP, editor. Pulmonary diseases and disorders. 1st ed. New York, Mc Graw-Hill, 1980;1388-96
|
12 |
Mackay CR, Terpe HJ, Stander R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82
DOI
|
13 |
Kim DC, Rha SH, Jeong JS, Hong SH. Expression of cell adhesion molecules CD44H and CD44v6 in colorectal carcinoma. Korean J Pathol 1998;32:655-62
|
14 |
Li H, Hamou M-F, de Tribolet N, et al. Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 1993;53:5345-9
|
15 |
Bourguignon LYW, Lokeshwar VB, Chen X, Kerrick WGL. Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol 1993;151:6634-44
|
16 |
Rudy W, Hofmann M, Schwartz-Albiez R, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each on individually suffices to confer metastatic behavior. Cancer Res 1993;149:249-57
|
17 |
Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rec tum 1994;37:921-6
DOI
|
18 |
Favrot MC, Combaret V, Lasset C. CD44-a new prognostic marker for neuroblastoma. N Eng J Med 1993;329:1965
|
19 |
Takigawa N, Segawa Y, Mandai K, Takata I, Jujimoto N. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathologic features. Lung Cancer 1997;18:147-57
DOI
ScienceOn
|
20 |
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-64
DOI
ScienceOn
|
21 |
Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63
DOI
ScienceOn
|
22 |
Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S
DOI
|
23 |
Ariza A, Mate JL, Ssamat M, et al. Standart and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995;177:363-8
DOI
|